HC Wainwright Reaffirms “Buy” Rating for KALA BIO (NASDAQ:KALA)

KALA BIO (NASDAQ:KALA)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $15.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 123.88% from the stock’s previous close.

Separately, Oppenheimer reiterated an “outperform” rating and issued a $15.00 price objective on shares of KALA BIO in a research report on Monday, August 19th.

KALA BIO Trading Down 0.9 %

Shares of NASDAQ KALA opened at $6.70 on Friday. KALA BIO has a twelve month low of $4.21 and a twelve month high of $10.97. The stock has a market cap of $30.89 million, a price-to-earnings ratio of -0.54 and a beta of -2.13. The company has a quick ratio of 3.07, a current ratio of 2.15 and a debt-to-equity ratio of 3.18. The company’s fifty day moving average is $6.02 and its 200-day moving average is $6.29.

KALA BIO (NASDAQ:KALA) last posted its earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share for the quarter, topping the consensus estimate of ($2.43) by $0.50. Equities research analysts predict that KALA BIO will post -11.76 EPS for the current year.

Institutional Investors Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP purchased a new stake in KALA BIO, Inc. (NASDAQ:KALA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th biggest position. SR One Capital Management LP owned 15.76% of KALA BIO at the end of the most recent reporting period. Hedge funds and other institutional investors own 24.61% of the company’s stock.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.